



## Neurocrine Biosciences to Present at the Morgan Stanley 15th Annual Global Healthcare Conference

September 6, 2017

**Live Audio Webcast Will be on September 11, 2017**

SAN DIEGO, Sept. 6, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Morgan Stanley 15<sup>th</sup> Annual Global Healthcare Conference in New York City.

The live presentation takes place on Monday, September 11 at 11:05am ET (8:05am PT). The presentation will be webcast and may be accessed on the Company's website at <http://www.neurocrine.com>.

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

### **About Neurocrine Biosciences, Inc.**

Neurocrine Biosciences is a San Diego based biotechnology company focused on neurologic, psychiatric and endocrine related disorders. The Company markets INGREZZA® (valbenazine) in the United States for the treatment of adults with tardive dyskinesia. INGREZZA is a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, and is the first and only FDA-approved product indicated for the treatment of adults with tardive dyskinesia. The Company's three late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc.; opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson's patients; and INGREZZA, a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette syndrome.

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at <http://www.neurocrine.com>.

View original content: <http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-morgan-stanley-15th-annual-global-healthcare-conference-300514871.html>

SOURCE Neurocrine Biosciences, Inc.

Investor Relations, [ir@neurocrine.com](mailto:ir@neurocrine.com)